APOE and Alzheimer disease: One notable example from Reiman et al. indicated that ApoE2 homozygotes have a 66% decrease in AD risk compared to ApoE2/ApoE3 heterozygotes, an 87% reduction relative to ApoE3 homozygotes, and a 99.6% reduction compared to ApoE4 homozygotes [10, 13].